
Kamloops, B.C., exploring city-owned and operated medical clinic
After watching another B.C. community launch a medical clinic owned and operated by the municipality, the City of Kamloops is considering whether the same model could solve a longstanding doctor shortage at the confluence of the North and South Thompson rivers.
In January, the City of Colwood, just outside Victoria on Vancouver Island, opened the Colwood Medical Clinic. Rather than having doctors see patients and also handle paperwork, like in a private practice setting, the city deals with administration and business issues so physicians can focus on providing care.
"The doctors of today like to work eight to 10 hours a day," Kamloops city councillor Kelly Hall told CBC's Daybreak Kamloops host Shelley Joyce. "They do their shift, they want to jump on their mountain bike, they want to go skiing at Sun Peaks. They want to enjoy quality time with their family."
Having the city handle the business side of running a clinic would give doctors that opportunity, he said.
Hall pitched the idea to the city's mayor and fellow council members, who in turn voted unanimously earlier this month to have city staff work up a clinic proposal.
The Colwood clinic came about in response to data showing that more than half of Colwood residents did not have a family doctor. The city plans to hire eight physicians in total, each able to take on about 1,250 patients.
Colwood Mayor Doug Kobayashi told The Canadian Press there have been a lot of applications, but they're only trying to recruit from out-of-province to avoid poaching physicians with active practices in other B.C. communities.
"You don't rob Peter to pay Paul," he said. "This is what's making the process a little bit slower than we were hoping."
WATCH | Colwood launches city-owned clinic:
To deal with a doctor shortage, this B.C. city has decided to start paying them directly
5 months ago
Duration 2:09
One Vancouver Island city is trying out a new health clinic model to address the provincial shortage of doctors. At Colwood's new city-run clinic, physicians will be paid as municipal employees. Michelle Gomez reports.
Kobayashi said the city-owned clinic currently has one doctor, and employment contracts are soon to be inked with two more. A fourth is expected to be on board by September.
He said several municipalities, including Kamloops, have inquired about the city-owned model, and though it has experienced "growing pains," the facility's first staff doctor has "become part of the community."
"She's been absolutely involved in our community, which is a great thing," he said. "It's just been phenomenal."
While Kamloops does have several family physicians, residents still struggle to find a GP. The city of some 100,000 is also lacking when it comes to in-person walk-in clinics.
"This is a game changer for the community, in my opinion," Hall said.
He suggested the doctors would be treated as city employees and have access to all the same benefits as city staff — including medical and dental benefits and access to a pension. They would show up to work, treat patients and go home, Hall said, without having to worry about pesky paperwork.
The Kamloops model would be different than the one in Colwood, he added, in particular because Kamloops is five times the size of the Island city.
But first, he said, they need to sell doctors on the city. He envisions a video explaining the benefits of living in the heart of B.C.'s Interior.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
20 minutes ago
- CTV News
Health risks linger as smoky skies and poor air quality persist
The special air quality statement has been lifted in Waterloo Region, but we're not in the clear yet. CTV's Alexandra Holyk explains. Smoky skies from western wildfires continue to pose health risks even as the air quality improves. On Tuesday, Environment and Climate Change Canada (ECCC) lifted the special air quality statement for most of southern Ontario and eastern parts of the country. It was in place over the long weekend as the Air Quality Health Index (AQHI) reached an 8, which is considered 'high risk.' 'The situation with the air quality has improved, which is why we don't have the special air quality statement in effect,' said ECCC weather spokesperson Alexandra Cournoyer. 'However, we still have some level of fine particles in the air.' The fine particles are known as PM 2.5 and are made of various pollutants, including soot, smoke, dust, and other elements found in burning wildfires. They are invisible to the naked eye and can cause serious health risks if breathed in. 'They can enter our bloodstream and put some stress on our heart and lungs and other organs of the body,' said Dr. Matthew Tenenbaum, the associate medical officer of health for Wellington-Dufferin-Guelph Public Health. 'How bad those are depends on how much smoke is in the air, as well as how long you're exposed,' he added. Tenenbaum said while everyone is at risk, some may feel it more than others. 'If you have asthma, if you have COPD (Chronic Obstructive Pulmonary Disease) or existing lung disease, that can make it that much harder for you,' he said. The smoke can also be tough on those with seasonal allergies, who may notice an increase in nose, throat and eye irritation. As for how to avoid breathing in the smoke, health officials recommend using high quality respirators or masks. 'Staying indoors is the key thing to protect yourself,' said Tenenbaum. 2025 wildfire season on track to be second-largest Summer 2025 is shaping up to be the second-largest wildfire season on modern record, said Ze'ev Gedalof, an associate professor in geography at the University of Guelph. According to the Canadian Interagency Forest Fire Centre, as of Tuesday afternoon, there were 746 active wildfires burning across the country, causing smoke that has billowed through Canada over the last few months. 'This really is the new normal,' Gedalof said. Cournoyer said ECCC has issued more special air quality statements this year compared to 2024. 'It's not going to stop burning,' Gedalof said. 'The smoke is going to keep blowing downwind from the boreal forest in Ontario, Manitoba, Saskatchewan, Alberta and even into B.C.,' he added. Gedalof said it's because the forest is out of equilibrium with the climate that's driving it. 'When it experiences these long, hot, dry summers, plus any sort of ignition – whether it's a cigarette butt or an unattended campfire or a lightning strike – when it does ignite, it's going to burn.' However, he said there are ways to reduce risks. 'Most ignitions are human caused,' Gedalof noted. 'So the fewer fires we start, the less smoke we have to breathe.'


Globe and Mail
41 minutes ago
- Globe and Mail
Pyoderma Gangrenosum Market Set for Expansion with Orphan Drug Designations and Pipeline Acceleration
The pyoderma gangrenosum treatment market is experiencing significant expansion, driven by increasing disease awareness, rising healthcare spending, and breakthrough therapies from key pharmaceutical players, including Johnson & Johnson, AbbVie, Amgen, Novartis, Eli Lilly and Company, Genentech, Galderma, Bristol Myers Squibb, Pfizer, LEO Pharma, and others. DelveInsight's " Pyoderma Gangrenosum Market Insight, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the pyoderma gangrenosum treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and pyoderma gangrenosum market forecasts through 2032, providing crucial insights for stakeholders in this specialized therapeutic area. According to DelveInsight's analysis, the pyoderma gangrenosum treatment market is projected to grow substantially with a notable CAGR during the forecast period (2023-2032), driven by enhanced understanding of disease mechanisms, improved diagnostic capabilities, and novel therapeutic approaches targeting the underlying immune system dysfunction. Download the Pyoderma Gangrenosum Market report to understand which factors are driving the therapeutic market @ Pyoderma Gangrenosum Market Trends. The epidemiological analysis reveals that pyoderma gangrenosum affects approximately 1 in 100,000 Americans, with women being somewhat more frequently affected than men. The condition most frequently occurs between the ages of 20 and 50, while less than 4 percent of incidents involve infants or teenagers. Furthermore, significant regional variations exist across the seven major markets, with the United States representing a substantial portion of the patient population. Market trends indicate growing recognition of the condition among healthcare providers, leading to improved diagnosis rates and earlier therapeutic intervention. The DelveInsight report further categorizes the pyoderma gangrenosum patient population based on disease severity, ulcer location, and associated comorbidities. This classification is essential for understanding treatment responses and developing targeted therapeutic strategies, as pyoderma gangrenosum often presents alongside inflammatory bowel disease, arthritis, and other autoimmune conditions. Discover evolving trends in the Pyoderma Gangrenosum patient pool forecasts @ Pyoderma Gangrenosum Epidemiology Analysis. Recent Developments In May 2025, InflaRx announced that the Independent Data Monitoring Committee (IDMC) recommended stopping their Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in the study. In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This designation provides incentives for developing treatments for rare diseases affecting fewer than 200,000 people in the United States. In January 2025, researchers reported successful treatment of PG complicated by myelofibrosis using a combination of systemic corticosteroid, adalimumab, and ruxolitinib. This represents an innovative approach for complex cases with comorbidities. Discover recent advancements in the Pyoderma Gangrenosum treatment landscape @ Pyoderma Gangrenosum Recent Developments. While there is no definitive cure for pyoderma gangrenosum, several treatment approaches focus on managing inflammation and promoting wound healing. Current therapeutic options include systemic corticosteroids, immunosuppressive agents, and topical treatments, though these approaches often provide limited efficacy and carry significant side effect burdens. The treatment landscape is evolving toward more targeted therapies that address the underlying inflammatory pathways responsible for tissue destruction. According to the DelveInsight report, the pyoderma gangrenosum therapies pipeline shows promising developments, with several novel treatments in late-stage clinical development. The pipeline focuses on therapeutics such as Vilobelimab (InflaRx) in Phase 3, Guselkumab (Janssen Scientific Affairs, LLC) in Phase 2, among others. Several companies are exploring innovative mechanisms of action to address the significant unmet medical needs in this rare disease area. Pyoderma gangrenosum pipeline development activities also include detailed analysis of collaborations, acquisitions, mergers, licensing agreements, and patent landscapes for emerging pyoderma gangrenosum therapies. The pyoderma gangrenosum treatment market is highly competitive, with major players including Johnson & Johnson, AbbVie, Amgen, Novartis, Eli Lilly and Company, Genentech, Galderma, Bristol Myers Squibb, Pfizer, LEO Pharma, and many others actively advancing therapies through robust research and development programs and strategic collaborations. These companies are leveraging their expertise in immunology and dermatology to develop targeted therapies for this challenging condition. Looking ahead, the pyoderma gangrenosum market is expected to witness continued innovation driven by rising disease awareness, incremental healthcare spending worldwide, and enhanced understanding of disease pathogenesis. The market expansion is anticipated to enable drug manufacturers to penetrate more effectively into this specialized therapeutic area. Companies and academic institutions are working collaboratively to assess challenges and identify opportunities that could influence pyoderma gangrenosum research and development activities. While significant progress is being made in understanding the immune system dysfunction underlying pyoderma gangrenosum, challenges remain in developing treatments that can achieve rapid ulcer healing, prevent disease recurrence, and improve overall quality of life for patients. Emerging therapeutic approaches focusing on novel immunomodulatory mechanisms, wound healing enhancement, and pain management hold promise for addressing these unmet needs and further transforming the treatment landscape. DelveInsight's analysis underscores that despite therapeutic advances, substantial opportunities remain for developing more effective, convenient, and accessible treatment options that can achieve durable remission and improved patient outcomes. The reimbursement landscape is also evolving to support innovative therapies for rare diseases, creating favorable market conditions for continued investment and development. As research continues and clinical understanding grows, the pyoderma gangrenosum market is poised for remarkable expansion and therapeutic innovation through 2032. Table of Contents 1. Key Insights 2. Executive Summary of Pyoderma Gangrenosum 3. Competitive Intelligence Analysis for Pyoderma Gangrenosum 4. Pyoderma Gangrenosum Market Overview at a Glance 5. Pyoderma Gangrenosum: Disease Background and Overview 6. Pyoderma Gangrenosum Patient Journey 7. Pyoderma Gangrenosum Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Pyoderma Gangrenosum Unmet Needs 10. Key Endpoints of Pyoderma Gangrenosum Treatment 11. Pyoderma Gangrenosum Marketed Products 12. Pyoderma Gangrenosum Emerging Therapies 13. Pyoderma Gangrenosum: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Pyoderma Gangrenosum 17. KOL Views 18. Pyoderma Gangrenosum Market Drivers 19. Pyoderma Gangrenosum Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Pyoderma Gangrenosum Pipeline Insight Pyoderma Gangrenosum pipeline insight provides comprehensive insights about the Pyoderma Gangrenosum pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Pyoderma Gangrenosum companies, including InflaRx GmbH, Janssen Scientific Affairs, LLC, and Boehringer Ingelheim, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.


CTV News
an hour ago
- CTV News
‘We've got you': School drives collecting supplies at Edmonton malls
The Pack the Pack initiative at Kingsway Mall aims to collect school supplies for Edmonton students. (CTV News Edmonton/Sean McClune) With back to school on the horizon, the cost of a child's school supplies list can be daunting for many families. But two initiatives are hoping to alleviate some of the pressure by collecting school supplies to be distributed to schools across the city. The Edmonton Public Schools Foundation (EPSF) has partnered with Kingsway Mall to 'pack the pack.' 'We are hoping to pack this backpack with new or unused school supplies in support of students this fall,' said EPSF acting director Catherine Bay. 'When students can start the year feeling prepared, they'll be a lot more confident in their learning.' A 'most needed' list of supplies is available on the EPSF website, and includes items like Duo-Tangs, notebooks, pencils, pencil crayons and binders. Bay said she's seen a need for supplies which has been growing every year. According to shopping lists from some Edmonton public schools, families with kids in elementary and junior high could be spending $50-$100 for a basic supply list. 'September tends to be a very expensive month for many families, and so the need just keeps increasing,' said Bay. 'Our goal is to be able to respond positively to students who do need that extra support. 'Don't worry, we've got you.' The drive is running until Sept. 6 at Kingsway Mall. SUPPLYDRIVE West Edmonton Mall is holding a school supplies drive until Aug. 17. (CTV News Edmonton/Sean McClune) But if you happen to be in the city's west end, West Edmonton Mall is also holding a drive in partnership with WEM Volkswagen and London Drugs to fill a bus with school supplies. Anna Alfonso, vice-president of marketing for West Edmonton Mall, said donations will be given to community partner Bent Arrow Traditional Healing Society and its family resource network. 'We are hoping for over 1,000 items donated,' said Alfonso. 'London Drugs has generously committed to providing backpacks and school supplies as well, and West Edmonton Mall is matching up to 100 items of school supplies donated.' SUPPLYDRIVE People can drop off new and unused school supplies at this Volkswagen van in West Edmonton Mall until Aug. 17. (CTV News Edmonton/Sean McClune) And while you might be picturing a big yellow school bus, the vehicle being filled is actually a Volkswagen bus that will be near Bourbon Street until Aug. 17. 'It's a fun play on what the city did with 'stuff a bus,'' said Alfonso. With files from CTV News Edmonton's Nahreman Issa